<p>加拿大温哥华，2025 年 12 月 16 日（GLOBE NEWSWIRE）——Clearmind Medicine Inc.（纳斯达克代码：CMND），（法兰克福证券交易所代码：CWY0）（“Clearmind” 或 “公司”）是一家临床阶段的生物技术公司，专注于发现和开发新型神经塑性药物，以解决主要的未得到充分治疗的健康问题。今天，公司宣布成功完成了其正在进行的 FDA 批准的 I/IIa 期临床试验的第二组患者招募，该试验评估 CMND-100，这是一种基于 MEAI 的口服药物候选者，用于治疗酒精使用障碍（AUD）。该组由六名患者组成，快速招募于三家顶级临床中心：约翰霍普金斯大学、特拉维夫索拉斯基医疗中心和哈达萨医疗中心。</p>
<p>这一里程碑是在最近完成的第一组患者招募之后，该组显示出令人鼓舞的顶线安全性和有效性数据，包括良好的安全性特征和减少渴求及戒断症状的初步信号。</p>
<p>第二组患者的快速招募——在极短的时间内完成——突显了合作临床中心的强大承诺和卓越的运营能力，强调了他们在推进 AUD 创新治疗方面的奉献精神，这种状况影响着全球数百万人的健康，且有效的治疗选择有限。</p>
<p>“我们对第二组患者的快速招募感到非常兴奋，这反映了患者和领先临床中心对 CMND-100 在转变 AUD 治疗潜力的高度关注，” Clearmind Medicine 首席执行官 Adi Zuloff-Shani 博士表示。“基于第一组的优秀结果，我们相信这一快速进展使我们能够生成更多有价值的数据，使我们更接近于提供一种突破性疗法，解决成瘾的根本原因，并具有更好的安全性特征。”</p>
<p>这项跨国 I/IIa 期试验旨在评估 CMND-100 在中度至重度 AUD 患者中的安全性、耐受性、药代动力学和初步有效性。第二组的给药预计将很快开始，顶线结果预计将在未来几个月内公布。</p>
<p><strong>关于 Clearmind Medicine Inc.</strong></p>
<p>Clearmind 是一家临床阶段的迷幻药物制药生物技术公司，专注于发现和开发新型迷幻药物，以解决广泛且未得到充分满足的健康问题，包括酒精使用障碍。其主要目标是研究和开发基于迷幻药的化合物，并尝试将其商业化为受监管的药物、食品或补充剂。</p>
<p>公司的知识产权组合目前包括十九个专利家族，拥有 31 项已授予的专利。公司打算在必要时为其化合物申请更多专利，并将保持机会主义，收购更多知识产权以扩展其组合。</p>
<p>Clearmind 的股票在纳斯达克交易所以 “CMND” 代码上市，在法兰克福证券交易所以 “CWY0” 代码上市。</p>
<p>欲了解更多信息，请访问：https://www.clearmindmedicine.com 或联系：</p>
<p>投资者关系</p>
<p>invest@clearmindmedicine.com</p>
<p>电话：（604）260-1566</p>
<p>美国：CMND@crescendo-ir.com</p>
<p>一般咨询</p>
<p>Info@Clearmindmedicine.com</p>
<p>www.Clearmindmedicine.com</p>
<p><strong>前瞻性声明：</strong></p>
<p>本新闻稿包含《私人证券诉讼改革法案》和其他证券法所定义的 “前瞻性声明”。诸如 “预计”、“预期”、“打算”、“计划”、“相信”、“寻求”、“估计” 等词语及其类似表达或变体旨在识别前瞻性声明。例如，当公司讨论推进针对 AUD 的创新治疗、患者和领先临床机构对 CMND-100 的高度关注、CMND-100 在转变 AUD 治疗方面的潜力以及其相信这一快速进展使其能够生成额外有价值的数据，从而更接近于提供一种解决成瘾根本原因并具有改进安全性特征的突破性疗法时，使用了前瞻性声明。前瞻性声明并非历史事实，而是基于管理层当前的期望、信念和预测，其中许多本质上具有不确定性。这些期望、信念和预测是以善意表达的。然而，无法保证管理层的期望、信念和预测将会实现，实际结果可能与前瞻性声明中所表达或指示的内容有重大差异。前瞻性声明受到风险和不确定性的影响，这可能导致实际表现或结果与前瞻性声明中所表达的内容有重大差异。有关影响公司的风险和不确定性的更详细描述，请参考公司不时向证券交易委员会（“SEC”）提交的报告，包括但不限于公司截至 2024 年 10 月 31 日的财政年度的 20-F 表格年报中详细列出的风险以及随后的 SEC 文件。前瞻性声明仅在声明发布之日有效。公司不承担更新前瞻性声明以反映实际结果、后续事件或情况、假设变化或影响前瞻性信息的其他因素变化的义务，除非适用的证券法要求。如果公司更新一项或多项前瞻性声明，不应推断公司将就此或其他前瞻性声明进行额外更新。提供的参考和链接仅为方便，网站上包含的信息并未被纳入本新闻稿的引用中。Clearmind 对第三方网站的内容不承担责任。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01qazBNaU0zTXpJME1Ua3hJelV3TURBNE5qa3pOQT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01qazBNaU0zTXpJME1Ua3hJelV3TURBNE5qa3pOQT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZjQyZDVkZWUtY2ZlMC00ZWFmLWI5MzMtZDA0NTRiMjliMzYyLTUwMDA4NjkzNC0yMDI1LTEyLTE2LWVu/tiny/Clearmind-Medicine-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZjQyZDVkZWUtY2ZlMC00ZWFmLWI5MzMtZDA0NTRiMjliMzYyLTUwMDA4NjkzNC0yMDI1LTEyLTE2LWVu/tiny/Clearmind-Medicine-Inc-.png"/></p>

CMND

<p>Clearmind Medicine Inc. 宣布其正在进行的 FDA 批准的 I/IIa 期临床试验中，第二组患者的招募已成功完成，该试验针对的是酒精使用障碍（AUD）的药物候选者 CMND-100。第二组由来自三个临床地点的六名患者组成。这是在第一组的安全性和有效性结果积极之后进行的。该试验旨在评估 CMND-100 的安全性、耐受性、药代动力学和初步有效性。第二组的给药将很快开始，预计在接下来的几个月内会公布初步结果</p>

<p>Vancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &#34;Company&#34;), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of patient enrollment for the second cohort in its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). The cohort consists of six patients, who were recruited rapidly across three premier clinical sites: Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.</p>
<div class="lb-trans"><p>加拿大温哥华，2025 年 12 月 16 日（GLOBE NEWSWIRE）——Clearmind Medicine Inc.（纳斯达克代码：CMND），（法兰克福证券交易所代码：CWY0）（“Clearmind” 或 “公司”）是一家临床阶段的生物技术公司，专注于发现和开发新型神经塑性药物，以解决主要的未得到充分治疗的健康问题。今天，公司宣布成功完成了其正在进行的 FDA 批准的 I/IIa 期临床试验的第二组患者招募，该试验评估 CMND-100，这是一种基于 MEAI 的口服药物候选者，用于治疗酒精使用障碍（AUD）。该组由六名患者组成，快速招募于三家顶级临床中心：约翰霍普金斯大学、特拉维夫索拉斯基医疗中心和哈达萨医疗中心。</p>
</div><p>This milestone follows the recent completion of the first cohort, which demonstrated encouraging top-line safety and efficacy data, including a favorable safety profile and preliminary signals of reduced cravings and withdrawal symptoms.</p>
<div class="lb-trans"><p>这一里程碑是在最近完成的第一组患者招募之后，该组显示出令人鼓舞的顶线安全性和有效性数据，包括良好的安全性特征和减少渴求及戒断症状的初步信号。</p>
</div><p>The swift enrollment of the second cohort—achieved in a remarkably short timeframe—highlights the strong commitment and operational excellence of the collaborating clinical centers, emphasizing their dedication to advancing innovative treatments for AUD, a condition affecting millions worldwide with limited effective options.</p>
<div class="lb-trans"><p>第二组患者的快速招募——在极短的时间内完成——突显了合作临床中心的强大承诺和卓越的运营能力，强调了他们在推进 AUD 创新治疗方面的奉献精神，这种状况影响着全球数百万人的健康，且有效的治疗选择有限。</p>
</div><p>“We are thrilled with the accelerated pace of enrollment for our second cohort, which reflects the high level of interest from both patients and leading clinical sites in CMND-100’s potential to transform AUD treatment,” stated Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. “Building on the excellent results from the first cohort, we believe that this rapid progress positions us to generate additional valuable data, bringing us closer to delivering a breakthrough therapy that addresses the root causes of addiction with an improved safety profile.”</p>
<div class="lb-trans"><p>“我们对第二组患者的快速招募感到非常兴奋，这反映了患者和领先临床中心对 CMND-100 在转变 AUD 治疗潜力的高度关注，” Clearmind Medicine 首席执行官 Adi Zuloff-Shani 博士表示。“基于第一组的优秀结果，我们相信这一快速进展使我们能够生成更多有价值的数据，使我们更接近于提供一种突破性疗法，解决成瘾的根本原因，并具有更好的安全性特征。”</p>
</div><p>The multinational Phase I/IIa trial is designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. Dosing for the second cohort is expected to commence shortly, with topline results anticipated in the coming months.</p>
<div class="lb-trans"><p>这项跨国 I/IIa 期试验旨在评估 CMND-100 在中度至重度 AUD 患者中的安全性、耐受性、药代动力学和初步有效性。第二组的给药预计将很快开始，顶线结果预计将在未来几个月内公布。</p>
</div><p><strong>About Clearmind Medicine Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Clearmind Medicine Inc.</strong></p>
</div><p>Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.</p>
<div class="lb-trans"><p>Clearmind 是一家临床阶段的迷幻药物制药生物技术公司，专注于发现和开发新型迷幻药物，以解决广泛且未得到充分满足的健康问题，包括酒精使用障碍。其主要目标是研究和开发基于迷幻药的化合物，并尝试将其商业化为受监管的药物、食品或补充剂。</p>
</div><p>The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.</p>
<div class="lb-trans"><p>公司的知识产权组合目前包括十九个专利家族，拥有 31 项已授予的专利。公司打算在必要时为其化合物申请更多专利，并将保持机会主义，收购更多知识产权以扩展其组合。</p>
</div><p>Shares of Clearmind are listed for trading on Nasdaq under the symbol &#34;CMND&#34; and the Frankfurt Stock Exchange under the symbol “CWY0.”</p>
<div class="lb-trans"><p>Clearmind 的股票在纳斯达克交易所以 “CMND” 代码上市，在法兰克福证券交易所以 “CWY0” 代码上市。</p>
</div><p>For further information, visit: https://www.clearmindmedicine.com or contact:</p>
<div class="lb-trans"><p>欲了解更多信息，请访问：https://www.clearmindmedicine.com 或联系：</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>invest@clearmindmedicine.com</p>
<div class="lb-trans"><p>invest@clearmindmedicine.com</p>
</div><p>Telephone: (604) 260-1566</p>
<div class="lb-trans"><p>电话：（604）260-1566</p>
</div><p>US: CMND@crescendo-ir.com</p>
<div class="lb-trans"><p>美国：CMND@crescendo-ir.com</p>
</div><p>General Inquiries</p>
<div class="lb-trans"><p>一般咨询</p>
</div><p>Info@Clearmindmedicine.com</p>
<div class="lb-trans"><p>Info@Clearmindmedicine.com</p>
</div><p>www.Clearmindmedicine.com</p>
<div class="lb-trans"><p>www.Clearmindmedicine.com</p>
</div><p><strong>Forward-Looking Statements:</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明：</strong></p>
</div><p>This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses advancing innovative treatments for AUD, the high level of interest from both patients and leading clinical sites in CMND-100, CMND-100’s potential to transform AUD treatment and its belief that that this rapid progress positions it to generate additional valuable data, bringing it closer to delivering a breakthrough therapy that addresses the root causes of addiction with an improved safety profile. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.</p>
<div class="lb-trans"><p>本新闻稿包含《私人证券诉讼改革法案》和其他证券法所定义的 “前瞻性声明”。诸如 “预计”、“预期”、“打算”、“计划”、“相信”、“寻求”、“估计” 等词语及其类似表达或变体旨在识别前瞻性声明。例如，当公司讨论推进针对 AUD 的创新治疗、患者和领先临床机构对 CMND-100 的高度关注、CMND-100 在转变 AUD 治疗方面的潜力以及其相信这一快速进展使其能够生成额外有价值的数据，从而更接近于提供一种解决成瘾根本原因并具有改进安全性特征的突破性疗法时，使用了前瞻性声明。前瞻性声明并非历史事实，而是基于管理层当前的期望、信念和预测，其中许多本质上具有不确定性。这些期望、信念和预测是以善意表达的。然而，无法保证管理层的期望、信念和预测将会实现，实际结果可能与前瞻性声明中所表达或指示的内容有重大差异。前瞻性声明受到风险和不确定性的影响，这可能导致实际表现或结果与前瞻性声明中所表达的内容有重大差异。有关影响公司的风险和不确定性的更详细描述，请参考公司不时向证券交易委员会（“SEC”）提交的报告，包括但不限于公司截至 2024 年 10 月 31 日的财政年度的 20-F 表格年报中详细列出的风险以及随后的 SEC 文件。前瞻性声明仅在声明发布之日有效。公司不承担更新前瞻性声明以反映实际结果、后续事件或情况、假设变化或影响前瞻性信息的其他因素变化的义务，除非适用的证券法要求。如果公司更新一项或多项前瞻性声明，不应推断公司将就此或其他前瞻性声明进行额外更新。提供的参考和链接仅为方便，网站上包含的信息并未被纳入本新闻稿的引用中。Clearmind 对第三方网站的内容不承担责任。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01qazBNaU0zTXpJME1Ua3hJelV3TURBNE5qa3pOQT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwMjk0MiM3MzI0MTkxIzUwMDA4NjkzNA=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZjQyZDVkZWUtY2ZlMC00ZWFmLWI5MzMtZDA0NTRiMjliMzYyLTUwMDA4NjkzNC0yMDI1LTEyLTE2LWVu/tiny/Clearmind-Medicine-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZjQyZDVkZWUtY2ZlMC00ZWFmLWI5MzMtZDA0NTRiMjliMzYyLTUwMDA4NjkzNC0yMDI1LTEyLTE2LWVu/tiny/Clearmind-Medicine-Inc-.png"/></p>

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100 | CMND Stock News

Clearmind Medicine 宣布成功完成正在进行的 FDA 批准的 CMND-100 I/IIa 期试验的第二组患者入组 | CMND 股票新闻